Clinical Trials Logo
  1. Home
  2. Stage IIB Prostate Cancer
  3. NCT02119858

Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery

Stage IIB Prostate Cancer Clinical Trial

Official title:
A Prospective Investigation of Near Infrared Fluorescence Imaging of Pelvic Lymph Nodes Using Indocyanine Green on the da Vinci Surgical System During Radical Prostatectomy and Pelvic Lymphadenectomy for Localized Prostate Cancer

Clinical Trial Summary

This clinical trial studies diffuse optical imaging with indocyanine green solution in imaging pelvic lymph nodes in patients with stage II prostate cancer undergoing surgery. Indocyanine green solution is a special dye that can help doctors see the lymph nodes and blood vessels during surgery when visualized under diffuse optical imaging. Indocyanine green solution may improve the ability to detect lymph nodes and may lead to improved accuracy of lymph node removal.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine the ability of indocyanine green (indocyanine green solution) (ICG) to highlight pelvic lymphatic tissue with fluorescence during robot assisted radical prostatectomy using near infrared fluorescence (diffuse optical imaging).

SECONDARY OBJECTIVES:

I. To evaluate the ability of this technique to improve lymph node yield, providing a potential therapeutic benefit to these patients by removing additional lymph nodes that may otherwise have been missed.

OUTLINE:

Patients receive indocyanine green transperineally and undergo diffuse optical imaging during robot-assisted laparoscopic radical prostatectomy with bilateral lymph node dissection using the da Vinci Robotic Surgical System.

After completion of study treatment, patients are followed up for 1-2 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02119858
Study type Interventional
Source City of Hope Medical Center
Contact
Status Completed
Phase Phase 1
Start date July 25, 2014
Completion date February 7, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT02217709 - Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer Phase 2
Completed NCT03233555 - Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer N/A
Completed NCT00103194 - Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer Phase 2
Completed NCT02250014 - The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer Phase 1
Active, not recruiting NCT01655836 - High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer Phase 1
Terminated NCT01340599 - Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery Phase 2
Active, not recruiting NCT01823562 - Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery Phase 1
Active, not recruiting NCT01923506 - Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery Phase 1
Completed NCT01433913 - Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery Phase 2
Completed NCT00589472 - Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer Phase 2
Active, not recruiting NCT02176902 - Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer N/A
Completed NCT01731912 - Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer N/A
Completed NCT01656304 - Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy Phase 2
Recruiting NCT03880422 - Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors N/A
Active, not recruiting NCT02446366 - Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery N/A
Completed NCT02048150 - Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer Phase 1
Withdrawn NCT01555632 - Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy N/A
Withdrawn NCT01859689 - Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer Phase 2
Completed NCT01023061 - Abiraterone Acetate, Prednisone, and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer Phase 2
Completed NCT00956163 - Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer Phase 0